steoarthritis (“OA”) is the most common joint disease with 12.1% of US adults showing symptoms in the knee and obesity being associated with a 3.5 fold prevalence of OA in US adults between 60-64 years of age. (Medtrack database).
The majority of treatments only address the pain associated with OA. Across the seven major markets of the U.S, France, Germany, Italy, Spain, the U.K and Japan the osteoarthritis market was worth $3.25B in 2014 and expected to grow at a Compound Annual Growth Rate of 17.8% to reach $10.49B by 2024 (GlobalData, 2016).
In 2015 our collaborator published:
In 2010 Dr Kwon and co-workers published a paper in the Journal of Korean Medical Science (2010; 25: 776-780) titled “Additive Effects of Intra-articular Injection of Growth Hormone and Hyaluronic Acid in Rabbit Model of Collagenase-induced Osteoarthritis”. In that study the co-injection of intra-articular HA and human Growth Hormone (hGH) was more effective than HA alone in the osteoarthritis model in terms of duration and severity of lameness, lower macroscopic scores of cartilage damage and histopathological scores of cartilage damage. In that study HA alone proved to be more effective than control (saline) on the same measures.
Dr Kwon was asked to collaborate on a similarly designed study to evaluate the effect of LAT8881 in the University Medical Center’s model.
In commenting on his study findings Dr Kwon MD, PhD said “These results are exciting because they provide early stage evidence in a rabbit model that LAT8881 may help to repair OA damaged tissue. LAT8881 appears to have retained the same beneficial effects as hGH in our rabbit model of collagenase-induced OA.” This evidence gives Lateral Pharma increased confidence that LAT8881 can be further developed to become an effective treatment for OA in both humans and companion animals.
Potential Utility of LAT8881 in Osteoarthritis This encouraging in-vivo efficacy data when combined with the highly favourable safety profile of LAT8881, proven in formal pre-clinical toxicology studies and six human clinical trials, provides strong rationale for use of the peptide to treat OA.
LAT8881 could offer further advantages in that it can be dosed in multiple forms including oral, transdermal, injection and intra-articular.